Reagents and instruments for immunology, cell biology and molecular biology.
 
> Dacarbazine [4342-03-4]

Dacarbazine [4342-03-4]

Print Print
Please log in

Cat# HY-B0078-1ml

Size : 10mM/1mL

Brand : MedChemExpress


Dacarbazine is a nonspecific antineoplastic (antineoplastic) alkylating agent. Dacarbazine inhibits T and B lymphocyte responses with IC50 of 50 and 10 μg/mL, respectively. Dacarbazine can be used in the study of metastatic malignant melanoma.

For research use only. We do not sell to patients.

Dacarbazine Chemical Structure

Dacarbazine Chemical Structure

CAS No. : 4342-03-4

This product is a controlled substance and not for sale in your territory.

Based on 9 publication(s) in Google Scholar

Other Forms of Dacarbazine:

  • Dacarbazine citrate Get quote
  • Dacarbazine hydrochloride Get quote
  • Dacarbazine (Standard) Get quote
  • Dacarbazine-d6 Get quote
Description

Dacarbazine is a nonspecific antineoplastic (antineoplastic) alkylating agent. Dacarbazine inhibits T and B lymphocyte responses with IC50 of 50 and 10 μg/mL, respectively. Dacarbazine can be used in the study of metastatic malignant melanoma[1][2][3][4][5].

In Vitro

Dacarbazine (6.25-500 μg/mL 48 h) combines with hyperthermia-induced cytotoxicity of A375 and MNT-1 melanoma cells[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Dacarbazine Related Antibodies

Cell Viability Assay[5]

Cell Line: A375, MNT-1
Concentration: 6.25, 12.5, 25, 50, 100, 200, 400, 500 μg/mL
Incubation Time: 24, 48, 72 h
Result: Inhibited cell viability in a concentration-dependent manner.

Cell Cycle Analysis[5]

Cell Line: A375, MNT-1
Concentration: 5.5, 115 μg/mL
Incubation Time: 48 h
Result: Decreased (9.3%) the percentage of A375 cells at the S phase and increased the number of cells at G2/M.
Decreased MNT-1 cells at G0/G1, increasing in cells at both S and G2/M phases.
Clinical Trial
Molecular Weight

182.18

Formula

C6H10N6O
CAS No.

4342-03-4
Appearance

Solid

Color

White to yellow

SMILES

O=C(C1=C(/N=N/N(C)C)NC=N1)N
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility
In Vitro: 

0.1 M HCL : 20 mg/mL (109.78 mM; ultrasonic and warming and heat to 60°C)

DMSO : 5 mg/mL (27.45 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 5.4891 mL 27.4454 mL 54.8908 mL
5 mM 1.0978 mL 5.4891 mL 10.9782 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 2 mg/mL (10.98 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

  • Protocol 2

    Add each solvent one by one:  50% PEG300    50% Saline

    Solubility: 5 mg/mL (27.45 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation

Purity: 99.96%

COA (254 KB) HNMR (252 KB) RP-HPLC (257 KB) MS (206 KB)

Handling Instructions (2659 KB)
References

  • [1]. Serrone, L., et al., Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res, 2000. 19(1): p. 21-34.  [Content Brief]

    [2]. Al-Badr AA, et al. Dacarbazine. Profiles Drug Subst Excip Relat Methodol. 2016;41:323-77.  [Content Brief]

    [3]. Rojo JM, et al. Inhibition of T and B lymphoblastic response by mithramycin, dacarbazine, prospidium chloride and peptichemio. Chemotherapy. 1983;29(5):345-51.  [Content Brief]

    [4]. Erdmann S, et al. Induced cross-resistance of BRAFV600E melanoma cells to standard chemotherapeutic dacarbazine after chronic PLX4032 treatment. Sci Rep. 2019 Jan 10;9(1):30.  [Content Brief]

    [5]. Salvador D, et al. Combined Therapy with Dacarbazine and Hyperthermia Induces Cytotoxicity in A375 and MNT-1 Melanoma Cells. Int J Mol Sci. 2022 Mar 25;23(7):3586.  [Content Brief]

  • [1]. Serrone, L., et al., Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res, 2000. 19(1): p. 21-34.

    [2]. Al-Badr AA, et al. Dacarbazine. Profiles Drug Subst Excip Relat Methodol. 2016;41:323-77.

    [3]. Rojo JM, et al. Inhibition of T and B lymphoblastic response by mithramycin, dacarbazine, prospidium chloride and peptichemio. Chemotherapy. 1983;29(5):345-51.

    [4]. Erdmann S, et al. Induced cross-resistance of BRAFV600E melanoma cells to standard chemotherapeutic dacarbazine after chronic PLX4032 treatment. Sci Rep. 2019 Jan 10;9(1):30.

    [5]. Salvador D, et al. Combined Therapy with Dacarbazine and Hyperthermia Induces Cytotoxicity in A375 and MNT-1 Melanoma Cells. Int J Mol Sci. 2022 Mar 25;23(7):3586.

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO / 0.1 M HCL 1 mM 5.4891 mL 27.4454 mL 54.8908 mL 137.2269 mL
5 mM 1.0978 mL 5.4891 mL 10.9782 mL 27.4454 mL
10 mM 0.5489 mL 2.7445 mL 5.4891 mL 13.7227 mL
15 mM 0.3659 mL 1.8297 mL 3.6594 mL 9.1485 mL
20 mM 0.2745 mL 1.3723 mL 2.7445 mL 6.8613 mL
25 mM 0.2196 mL 1.0978 mL 2.1956 mL 5.4891 mL
0.1 M HCL 30 mM 0.1830 mL 0.9148 mL 1.8297 mL 4.5742 mL
40 mM 0.1372 mL 0.6861 mL 1.3723 mL 3.4307 mL
50 mM 0.1098 mL 0.5489 mL 1.0978 mL 2.7445 mL
60 mM 0.0915 mL 0.4574 mL 0.9148 mL 2.2871 mL
80 mM 0.0686 mL 0.3431 mL 0.6861 mL 1.7153 mL
100 mM 0.0549 mL 0.2745 mL 0.5489 mL 1.3723 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Dacarbazine Related Classifications

  • Cell Cycle/DNA Damage Apoptosis
  • Nucleoside Antimetabolite/Analog Apoptosis
Help & FAQs

Keywords:

Dacarbazine4342-03-4Imidazole CarboxamideNucleoside Antimetabolite/AnalogApoptosisMelanomaA375MNT-1AntitumorInhibitorinhibitorinhibit

You might also be interested by the following products:



Cat#
Description
Cond.
Price Bef. VAT
HY-N0736-1ml
Coptisine (chloride) [6020-18-4]
 10mM/1mL